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Abstract
Di-n-butyltin, tri-n-butyltin and triphenyltin terebates were screened against several human tumour
cell lines and found comparably or more active than carboplatin, cis-platin, 5-fluorouracil,
methotrexate and doxorubicin, some reference compounds used clinically.
Introduction
A large number of di- and triorganotin carboxylates exhibit interesting in vitro antitumour activities
against human tumour cell lines(I).
Several 1"1 and 1:2 condensation compounds of di-n-butyltin oxide with mono-(2a), di-(2b), tri-,
tetra-(2c) and pentafluorobenzoic acids(2d) are among such substances. Di-n-butyltin compounds
are generally much more active than other diorganotin compounds.
Many substituted triphenyltin benzoates(3) are even more active In contrast, tri-n-butyltin
difluorobenzoates(4) are less active than the corresponding trilhenyltin and di-n-butyltin
compounds.
A series of tri- and diorganotin steroidcarboxylates were recently screened against seven human
tumour cell lines, MCF-7 and EVSA-T, two breast cancers, WiDr, a colon cancer, IGROV, an ovarian
cancer, M19 MEL, a melanoma, A498, a renal cancer, and H226, a non small cell lung cancer. The in
vitro antitumour activities of the di-n-butyltin compound lie between those of 5-fluorouracil and
doxorubicin. The activities of the triorganotin compounds are comparable to those of methotrexate
or doxorubicin(5).
In the frame of our interest in biologically relevant organotin carboxylates, we report the synthesis
and antitumour properties of di- and triorganotin derivatives of dl-terebic acid.
Results and Discussion
Di-n-butyltin diterebate, (H902C6-COO)2SnBu 2, compound 1, tri-n-butyltin terebate, (1"’190206-
COO)SnBu3, compound 2, and triphenyltin terebate, (HgO2C6-COO)SnPh3, compound 3, were
synthesized by the condensation of dl-terebic acid, (H902C6-COOH) with respectively di-n-butyltin
oxide, tri-n-butyltin acetate and triphenyltin hydroxide.
They were characterized by 1H NMR, through multiplet patterns and resonance integrals, by 13C
NMR, supported by DEPT experiments, by 17Sn NMR and by 119Sn M6ssbauer spectroscopy (see
Experimental Section).
The 1j(13C-119/117Sn) coupling constants (567/542 Hz) and the 117Sn chemical shift (-131.6 ppm) of
compound 1 lie in the ranges characteristic for di-n-butyltin dibenzoates(6) and -disalicylates(7)(8)
displaying a pseudo-octahedral or alternatively trapezoidal bipyramidal structure with two n-butyl
groups in axial positions. The carboxylates coordinate the tin atom in the bidentate mode in
equatorial positions with two adjacent short and two longer Sn-O bonds. All other NMR resonances
are, accordingly, as expected for this type of structure.
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The 1j(13C-119/117Sn) coupling constants (354/338 Hz) and the 117Sn chemical shift (+125.4 ppm)
of compound 2 are compatible with a monomeric tetrahedral structure found recently for a series of
tri-n-butyl fluorobenzoates in solution(4), in agreement with earlier coupling data described by
Holecek and Lycka(9).
The 1j(13C-119/117Sn) coupling constants (648/618 Hz) and the 117Sn chemical shift (-97.6 ppm) of
compound 3 are again in agreement with a tetrahedral monomeric structure(2)(10)(11).
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Antitumour activities
The in vitro antitumour activities of compounds 1, 2 and 3 against several human-cell lines, MCF-7
and EVSA-T, two breast cancers, WiDr, a colon cancer, IGROV, an ovarian cancer, M19 MEL, a
melanoma, A498, a renal cancer, and H226, a non small cell lung cancer, are displayed in table 1,
together with those of some reference compounds used clinically: carboplatin, cis-platin, 5-
fluorouracil, methotrexate and doxorubicin.
Table clearly shows that the compounds are comparably to more active than methotrexate and
doxorubicin in vitro against almost all cell lines. The very high activity of compounds 2 and 3 against
EVSA-T as well as of compound 2 in general should be outlined.
Experimental part
Syntheses
Compounds 1 to 3 were prepared by adding 5 mmole of di-n-butyltin oxide, tri-n-butyltin acetate or
triphenyltin hydroxide, respectively, to a solution of 10 mmole, 5 mmole or 5 mmole of terebic acid
in 150 cm3 toluene and 50 cm3 ethanol. After refluxing for 6 h, distilling off the ternary azeotrope
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water/toluene/ethanol with a Dean Stark funnel and half of the remaining solvent, the resulting
mixture was cooled down to room temperature, filtered and evaporated under vacuum. The residue
was recrystallized from the appropriate solvent.
Compounds MCF-7 EVSA-T WiDr IGROV M19 MEL A498 M226
1 27 25 134 18 27 61 104
2 3 <3 11 4 11 15 8
3 17 <3 17 19 42 58 39
Carboplatin(14) 10500 4500 3500 2400 5500 8000 25000
Cisplatin(14) 400 920 550 230 780 1200 31 58
5-Fluorouracil(14) 350 720 440 850 310 340 5300
Methotrexate(14) 5 26 7 20 8 6 70
Doxorubicin(14) 25 3 8 150 21 55 80
Table 1. In vitro antitumour activities (ng/mL) of compounds 1 to 3, together with those of some
reference compounds used clinically.
Characterization
MSssbauer data: QS: quadrupole splitting; IS: isomer shift; r’l and F2: line widths, all in mm/s.
NMR data: all spectra were acquired from CDCI3 solutions and referenced to the residual CHCI3
resonance at 7.24 ppm for the H spectrum, to the central 13CDCI3 resonance at 77.0 ppm for the
13C spectrum and to E,(119Sn) 37.290665 for the 119Sn spectra(12).
Abbreviations for coupling patterns: s singlet; d doublet; triplet; td triplet of doublets; tq
triplet of quartets; b broad resonance; m complex pattern; nv non visible; coupling constants
are given in Hz between parentheses for nJ(H-H) for 1H spectra. Other coupling constants are
indicated explicitely.
Compound 1: recrystallization solvent: chlorofom/n-hexane; m.p.: 98-100C; yield: 85%;
MSssbauer data: QS: 3.44; IS: 1.34; FI: 0.99; F2: 0.91; 1H NMR data: 2.988, dd (18, 9): H-2a;
2.700, dd (18, 9): H-2b; 3.196, dd (9, 9): H-3; 1.581, s: H-5a; 1.348, s: H-5b; 1.62 1.64, m: H-7 &
H-8; 1.25 1.40, m: H-9; 0.873, (7): H-10; 13C NMR data: C-1: 174.1; C-2: 32.5; C-3: 50.5; C-4:
84.5; C-5a" 28.5; C-5b: 23.5; C-6: 179.5; C-7" 25.9 [1j(119/117Sn-130) 573/550]; C-8:26.7
[2j(119/117Sn-13C) 31]; C-9:26.4 [3j(119/117Sn-13C) 100/96]; C-10: 13.5; 119Sn NMR data:-134.0.
Compound 2" recrystallization solvent: petroleum ether; m.p.: 50-51C; yield: 95%; MSssbauer
data: QS: 3.77; IS: 1.47; ]-’1: 0.85; [’2: 0.86; 1H NMR data: 2.985, dd (17, 10): H-2a; 2.622, dd (17,
8): H-2b; 3.121, dd (10, 8): H-3; 1.562, s: H-5a; 1.297, s: H-5b; 1.50- 1.65, m: H-7 & H-8; 1.20
1.40, m: H-9; 0.878, (7): H-10; 130 NMR data: C-1: 174.4; C-2: 32.7; C-3: 51.4; C-4: 84.8; C-5a:
28.5; C-5b: 23.3; C-6: 174.8; C-7:16.7 [1j(119/117Sn-13C) 356/338]; C-8:27.8 [2j(119/117Sn-13C)
21]; C-9:27.0 [3j(119/117Sn-130) 64]; C-10: 13.6; 119Sn NMR data: 123.4.
Compound 3: recrystallization solvent: ethanol/petroleum ether; m.p.: 125-126C; yield: 95%;
MSssbauer data: QS: 3.52; IS: 1.31; [1: 0.82; F2: 0.79; 1H NMR data: 3.065, dd (18, 10): H-2a;
2.669, dd (18, 9): H-2b; 3.231, dd (10, 9): H-3; 1.585, s: H-5a; 1.114, s: H-5b; 7.70-7.80, m: H-8;
7.30-7.50, m: H-9 & H-10; 13C NMR data: C-1: 174.5; C-2: 32.7; C-3: 50.8; C-4: 84.8; C-5a: 28.5; C-
5b: 23.2; C-6: 175.6; C-7:137.5 [1j(119/117Sn-13C) 648/618]; C-8:136.9 [2j(119/117Sn-130)
51/49]; C-9:129.1 [3j(119/117Sn-13C)= 65/62]; C-10:130.5 [4j(119/117Sn-13C)= 13]; 119Sn NMR
data: -98.3.
Instruments
All NMR spectra were recorded on a Bruker AC250 instrument, using a QNP probe tuned at
250.13, 62.93 and 93.28 MHz for 1H, 13C and 19Sn nuclei, respectively.
MSssbauer spectra were obtained as described previously(8).
In vitro tests
The following human tumor cell lines were used: MCF7 Breast cancer- EVSA-T Breast cancer
WiDr Colon cancer IGROV Ovarian cancer- M19 MEL Melanoma A498 Renal cancer H226 Non
small cell lung cancer.
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MCF7 is estrogen receptor ER+/progesterone receptor PgR+ and EVSA-T is ER-/PgR-.
Cell lines WIDR M19 MEL, A498, IGROV and H226 belong to the currently used anti-cancer
screening panei of the National Cancer Institute, USA(13). The in vitro cytotoxicity of the
compounds was determined using SRB(14) as a cell viability test.
Prior to the experiments a mycoplasma test was carried out on all cell lines and found to be
negative. All cell lines were maintained in a continuous logarithmic culture in RPMI 1640 medium
with Hepes and phenol red. The medium was supplemented with 10% FCS, penicillin 100
IU/ml:md streptomycin 100 g/ml. The cells were mildly trypsinized for passage and for use in
experiments. RPMI and FCS were obtained from Life technologies (Paisley, Scotland). SRB,
DMSO, penicllin and streptomycin were obtained from Sigma (St. Louis, MO, USA), TCA and acetic
acid from Baker B.V. (Deventer, NL) and PBS from NPBI B.V. (Emmer-Compascuum, NL).
The test and reference compounds were dissolved to a concentration of 238095 ng/ml in full
medium, by 21 fold dilution of a DMSO solution which contained mg compound / 200 ILtl. The
experiment was started on day 0.
On day 0 150 !1 of trypsinized tumor cells (1500 2000 cells/well) were plated in 96-wells flatbottom
microtiter plates (falcon 3072, BD). The plates were preincubated 48 hr at 37C, 8,5 % CO2 to allow
the cells to adhere.
On day 2, a three fold dilution sequence of ten steps was made in full medium, starting with the
238095 ng/ml stock solution. Every dilution was used in quadruplicate by adding 50 1 to a column
of four wells.
This results in a highest concentration of 59523 ng/ml present in column 12. Column 2 was used
for the blank. To column PBS was added to diminish interfering evaporation.
On day 7 the incubation was terrninated by washing the plate twice with PBS. Subsequently the
cells were fixed with 10% trichloroacetic acid in PBS and placed at 4C for one hour. After five
washings with tap water, the cells were stained for at least 15 minutes with 0,4% SRB dissolved in
1% acetic acid. After staining the cells were washed with 1% acetic acid to remove the unbound
stain. The plates were air dried and the bound stain was dissolved in 150 !1 tris base. The
absorbance was read at 540 nm using an automated microplate reader (Labsystems Multiskan MS).
Data were used for construction of concentration-response curves and determination of the ID50
value by use of Deltasoft 3 software.
All raw data and the mastercopy of this report have been filed in the archives of the laboratory of
medical oncology of the Rotterdam Academical hospital.
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